ECM
OMED

Element Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Element Capital Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-25,249
Closed -$114K – 190
2017
Q3 		$114K Sell
25,249
-65,810
-72% -$267K 0.05% 49
2017
Q2 		$303K Buy
+91,059
New +$378K 0.06% 73

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Element Capital Management's OMED Position: Q4 2017 in Review

Element Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q4 2017, closing a stake of 25,249 shares — an estimated $114K sold.

Element Capital Management first reported a position in OMED in Q2 2017 and held it in 2 quarters. The position peaked at $303K in Q2 2017. 69 funds tracked by Wall St. Rank hold OMED as of Q4 2017.

  • Element Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Element Capital Management sold 25,249 OncoMed Pharmaceuticals, Inc. shares in Q4 2017, an estimated $114K.
  • Element Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
  • Element Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $303K in Q2 2017.
  • 69 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q4 2017.

Based on Element Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.